#1002, Dana Farber Cancer Institute — Boston, Massachusetts

#1002, Dana Farber Cancer Institute is a clinical research site located in Boston, Massachusetts, United States 02215.

Crixeo Health Trust Score: 55/100 (POOR). This profile has not yet been claimed by the site owner.

#1002, Dana Farber Cancer Institute has participated in 2 clinical trials with 1 currently active.

Therapeutic areas: Advanced Solid Tumor.

Sponsors: Repare Therapeutics, Debiopharm International SA.

Sponsor Feasibility Report

Trust Score: 55/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for #1002, Dana Farber Cancer Institute?

#1002, Dana Farber Cancer Institute has a Crixeo Trust Score of 55/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has #1002, Dana Farber Cancer Institute conducted?

#1002, Dana Farber Cancer Institute has 2 clinical trials on record, with 1 currently active. Their work covers Advanced Solid Tumor.

Is #1002, Dana Farber Cancer Institute accredited by Crixeo Health?

#1002, Dana Farber Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about #1002, Dana Farber Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.